EMA

EMA Withdraws Tavneos from the Market: Reasons for Recall and Medical Uses

by

The European Medicines Agency (EMA) has recommended the withdrawal of the marketing authorization for Tavneos (avacopan), a medication used to treat severe active granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). This regulatory decision follows a comprehensive review of the drug’s benefit-risk profile, leading to the conclusion that the clinical data provided does not sufficiently … Read more

Eli Lilly’s Retatrutid Achieves Weight Loss Comparable to Gastric Bypass; EMA Recommends Wegovy Pill Approval

by

The landscape of obesity treatment is undergoing a fundamental transformation as pharmaceutical innovation begins to mirror the clinical outcomes historically reserved for bariatric surgery. As a physician and health journalist, I have followed the evolution of metabolic medicine for over a decade, and the current shift toward highly potent injectable therapies represents a significant milestone … Read more

COVID Tech Offers Hope for Melanoma Patients: Fewer Cases Reported

by

COVID-19 Technologies Offer New Hope for Melanoma Patients Recent advancements stemming from ⁤research accelerated by the COVID-19‍ pandemic⁤ are showing promising results⁢ in the ‍fight against melanoma, the ⁣deadliest form of skin cancer. Specifically, technologies developed for mRNA vaccine creation and rapid diagnostics are being repurposed to enhance immunotherapy effectiveness and improve early detection of … Read more

>Multiple Myeloma: J&J Treatment Shows 83.4% Progression-Free at 3 Years

by

2026-01-19 12:50:00 Mieloma múltiple: tratamiento de J&J muestran 83,4% de pacientes libres de progresión a 3 años Johnson & Johnson pidió a la Agencia Europea de Medicamentos (EMA) aprobar la combinación de Tecvayli (teclistamab) y Darzalex Faspro (daratumumab + hialuronidasa-fihj) como tratamiento de segunda línea para mieloma múltiple refractario o recaído, apoyada en un ensayo … Read more